RT Journal Article
T1 Endogenous Circulating Sex Hormone Concentrations and Colon Cancer Risk in Postmenopausal Women: A Prospective Study and Meta-Analysis
A1 Mori, Nagisa
A1 Keski-Rahkonen, Pekka
A1 Gicquiau, Audrey
A1 Rinaldi, Sabina
A1 Dimou, Niki
A1 Harlid, Sophia
A1 Harbs, Justin
A1 Van Guelpen, Bethany
A1 Aune, Dagfinn
A1 Cross, Amanda J.
A1 Tsilidis, Konstantinos K.
A1 Severi, Gianluca
A1 Kvaskoff, Marina
A1 Fournier, Agnes
A1 Kaaks, Rudolf
A1 Fortner, Renee Turzanski
A1 Schulze, Matthias B.
A1 Jakszyn, Paula
A1 Sanchez, Maria-Jose
A1 Colorado-Yohar, Sandra M.
A1 Ardanaz, Eva
A1 Travis, Ruth
A1 Watts, Eleanor L.
A1 Masala, Giovanna
A1 Krogh, Vittorio
A1 Tumino, Rosario
A1 Sacerdote, Carlotta
A1 Panico, Salvatore
A1 Bueno-de-Mesquita, Bas
A1 Gram, Inger Torhild
A1 Waaseth, Marit
A1 Gunter, Marc J.
A1 Murphy, Neil
K1 Estrogen plus progestin
K1 Colorectal-cancer
K1 Free testosterone
K1 Binding globulin
K1 Estradiol
K1 Rationale
K1 Cohort
K1 Serum
AB Background: Observational studies have consistently reported that postmenopausal hormone therapy use is associated with lower colon cancer risk, but epidemiologic studies examining the associations between circulating concentrations of endogenous estrogens and colorectal cancer have reported inconsistent results. Methods: We investigated the associations between circulating concentrations of estrone, estradiol, free estradiol, testosterone, free testosterone, androstenedione, dehydroepiandrosterone (DHEA), progesterone, and sex hormone-binding globulin (SHBG) with colon cancer risk in a nested case-control study of 1028 postmenopausal European women (512 colon cancer cases, 516 matched controls) who were non-current users of exogenous hormones at blood collection. Multivariable conditional logistic regression models were used to compute odds ratios and 95% confidence intervals to evaluate the association between circulating sex hormones and colon cancer risk. We also conducted a dose-response meta-analysis of prospective studies of circulating estrone and estradiol with colorectal, colon, and rectal cancer risk in postmenopausal women. All statistical tests were 2-sided. Results: In the multivariable model, a nonstatistically significantly positive relationship was found between circulating estrone and colon cancer risk (odds ratio per log(2) 1-unit increment = 1.17 [95% confidence interval = 1.00 to 1.38]; odds ratio(quartile4-quartile1) = 1.33 [95% confidence interval = 0.89 to 1.97], P-trend = .20). Circulating concentrations of estradiol, free estradiol, testosterone, free testosterone, androstenedione, DHEA, progesterone, and SHBG were not associated with colon cancer risk. In the dose-response meta-analysis, no clear evidence of associations were found between circulating estradiol and estrone concentrations with colorectal, colon, and rectal cancer risk. Conclusion: Our observational and meta-analysis results do not support an association between circulating concentrations of endogenous sex hormones and colon or rectal cancer in postmenopausal women.
PB Oxford univ press
YR 2021
FD 2021-09-28
LK https://hdl.handle.net/10668/24664
UL https://hdl.handle.net/10668/24664
LA en
DS RISalud
RD Apr 7, 2025